RE:RE:Pharma faces looming patent cliff - seller's market in bioThis challenging issue facing Big Pharma is not going away soon, and the way out is through M&A that will be utilizing the US$1.5 Trillion in firepower that Big Pharma presently has in reserve. And competition for late stage Phase 3-ready immuno-oncology assets will be fierce.